Circulating Levels of Endotrophin Are Prognostic for Long-Term Mortality after AKI.
AKI
acute kidney injury and ICU nephrology
basic science
biomarker
collagen type VI
endotrophin
fibrosis
peptide fragments
prognosis
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
26 05 2022
26 05 2022
Historique:
received:
13
07
2021
accepted:
01
03
2022
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
AKI involves a rapid decrease in kidney function that may be associated with structural damage. Early markers predicting AKI are emerging, but tools to assess patients' long-term health risks after AKI are still lacking. Endotrophin (ETP) is a bioactive molecule released during the formation of collagen type VI. We evaluated the potential of circulating ETP as a prognostic biomarker of adverse outcomes after AKI. We measured ETP in plasma samples collected 1 year after an episode of AKI, using the PRO-C6 ELISA in 801 patients (393 patients with AKI and 408 controls) from the prospective AKI Risk in Derby (ARID) study (ISRCTN25405995), who were then followed until year 3. Kidney disease progression was defined as ≥25% decline in eGFR combined with a decline in CKD stage. ETP levels were significantly higher in the AKI group compared with controls ( Patients in the AKI group had higher levels of plasma ETP at year 1 as compared with those who had not had AKI. In the AKI group, ETP levels predict kidney disease progression and mortality. Because ETP is a profibrotic molecule, our findings may indicate that ETP identifies patients with active fibrogenesis after AKI, suggestive of long-term renal remodeling, which is associated with patient outcome.
Sections du résumé
Background
AKI involves a rapid decrease in kidney function that may be associated with structural damage. Early markers predicting AKI are emerging, but tools to assess patients' long-term health risks after AKI are still lacking. Endotrophin (ETP) is a bioactive molecule released during the formation of collagen type VI. We evaluated the potential of circulating ETP as a prognostic biomarker of adverse outcomes after AKI.
Methods
We measured ETP in plasma samples collected 1 year after an episode of AKI, using the PRO-C6 ELISA in 801 patients (393 patients with AKI and 408 controls) from the prospective AKI Risk in Derby (ARID) study (ISRCTN25405995), who were then followed until year 3. Kidney disease progression was defined as ≥25% decline in eGFR combined with a decline in CKD stage.
Results
ETP levels were significantly higher in the AKI group compared with controls (
Conclusions
Patients in the AKI group had higher levels of plasma ETP at year 1 as compared with those who had not had AKI. In the AKI group, ETP levels predict kidney disease progression and mortality. Because ETP is a profibrotic molecule, our findings may indicate that ETP identifies patients with active fibrogenesis after AKI, suggestive of long-term renal remodeling, which is associated with patient outcome.
Identifiants
pubmed: 36128492
doi: 10.34067/KID.0000422021
pii: 02200512-202205000-00006
pmc: PMC9438419
doi:
Substances chimiques
Biomarkers
0
Collagen Type VI
0
Peptide Fragments
0
endotrophin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-817Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
F. Genovese, M.A. Karsdal, and D.G.K. Rasmussen report being full-time employees at, and holding stock in, Nordic Bioscience. N. Sparding reports being a full-time employee at Nordic Bioscience and the University of Copenhagen. All remaining authors have nothing to disclose.
Références
Lewington AJP, Cerdá J, Mehta RL: Raising awareness of acute kidney injury: A global perspective of a silent killer. Kidney Int 84: 457–467, 2013 https://doi.org/10.1038/ki.2013.153
doi: 10.1038/ki.2013.153
Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, Bell M, Forni L, Guzzi L, Joannidis M, Kane-Gill SL, Legrand M, Mehta R, Murray PT, Pickkers P, Plebani M, Prowle J, Ricci Z, Rimmelé T, Rosner M, Shaw AD, Kellum JA, Ronco C: Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative Consensus Conference: A consensus statement. JAMA Netw Open 3: e2019209, 2020 https://doi.org/10.1001/jamanetworkopen.2020.19209
doi: 10.1001/jamanetworkopen.2020.19209
Horne KL, Packington R, Monaghan J, Reilly T, McIntyre CW, Selby NM: The effects of acute kidney injury on long-term renal function and proteinuria in a general hospitalised population. Nephron Clin Pract 128: 192–200, 2014 https://doi.org/10.1159/000368243
doi: 10.1159/000368243
National Kidney Foundation. KDIGO clinical practice guideline for acute kidney injury (AKI). Available at https://kdigo.org/guidelines/acute-kidney-injury/ . Accessed July 1, 2021
Devarajan P: The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 17: 469–479, 2010 https://doi.org/10.1053/j.ackd.2010.09.002
doi: 10.1053/j.ackd.2010.09.002
Oh DJ: A long journey for acute kidney injury biomarkers. Ren Fail 42: 154–165, 2020 https://doi.org/10.1080/0886022X.2020.1721300
doi: 10.1080/0886022X.2020.1721300
Horne KL, Shardlow A, Taal MW, Selby NM: Long term outcomes after acute kidney injury: Lessons from the ARID Study. Nephron 131: 102–106, 2015 https://doi.org/10.1159/000439066
doi: 10.1159/000439066
Katsuda S, Okada Y, Minamoto T, Oda Y, Matsui Y, Nakanishi I: Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb 12: 494–502, 1992 https://doi.org/10.1161/01.ATV.12.4.494
doi: 10.1161/01.ATV.12.4.494
Groulx JF, Gagné D, Benoit YD, Martel D, Basora N, Beaulieu JF: Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol 30: 195–206, 2011 https://doi.org/10.1016/j.matbio.2011.03.002
doi: 10.1016/j.matbio.2011.03.002
Aigner T, Hambach L, Söder S, Schlötzer-Schrehardt U, Pöschl E: The C5 domain of Col6A3 is cleaved off from the Col6 fibrils immediately after secretion. Biochem Biophys Res Commun 290: 743–748, 2002 https://doi.org/10.1006/bbrc.2001.6227
doi: 10.1006/bbrc.2001.6227
Heumüller SE, Talantikite M, Napoli M, Armengaud J, Mörgelin M, Hartmann U, Sengle G, Paulsson M, Moali C, Wagener R: C-terminal proteolysis of the collagen VI α3 chain by BMP-1 and proprotein convertase(s) releases endotrophin in fragments of different sizes. J Biol Chem 294: 13769–13780, 2019 https://doi.org/10.1074/jbc.RA119.008641
doi: 10.1074/jbc.RA119.008641
Fenton A, Jesky MD, Ferro CJ, Sørensen J, Karsdal MA, Cockwell P, Genovese F: Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS One 12: e0175200, 2017 https://doi.org/10.1371/journal.pone.0175200
doi: 10.1371/journal.pone.0175200
Sun S, Henriksen K, Karsdal MA, Byrjalsen I, Rittweger J, Armbrecht G, Belavy DL, Felsenberg D, Nedergaard AF: Collagen type III and VI turnover in response to long-term immobilization. PLoS One 10: e0144525, 2015 https://doi.org/10.1371/journal.pone.0144525
doi: 10.1371/journal.pone.0144525
Yepes-Calderón M, Sotomayor CG, Rasmussen DGK, Hijmans RS, Te Velde-Keyzer CA, van Londen M, van Dijk M, Diepstra A, Berger SP, Karsdal MA, Bemelman FJ, de Fijter JW, Kers J, Florquin S, Genovese F, Bakker SJL, Sanders JS, Van Den Born J: Biopsy-controlled non-invasive quantification of collagen type VI in kidney transplant recipients: A post-hoc analysis of the MECANO Trial. J Clin Med 9: 3216, 2020 https://doi.org/10.3390/jcm9103216
doi: 10.3390/jcm9103216
Sparding N, Genovese F, Rasmussen DGK, Karsdal MA, Neprasova M, Maixnerova D, Satrapova V, Frausova D, Hornum M, Bartonova L, Honsova E, Kollar M, Koprivova H, Hruskova Z, Tesar V: Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis [published online ahead of print April 29, 2021]. Nephrol Dial Transplant 10.1093/ndt/gfab163
doi: 10.1093/ndt/gfab163
Rasmussen DGK, Fenton A, Jesky M, Ferro C, Boor P, Tepel M, Karsdal MA, Genovese F, Cockwell P: Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Sci Rep 7: 17328, 2017 https://doi.org/10.1038/s41598-017-17470-3
doi: 10.1038/s41598-017-17470-3
Rasmussen DGK, Hansen TW, von Scholten BJ, Nielsen SH, Reinhard H, Parving HH, Tepel M, Karsdal MA, Jacobsen PK, Genovese F, Rossing P: Higher collagen VI formation is associated with all-cause mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care 41: 1493–1500, 2018 https://doi.org/10.2337/dc17-2392
doi: 10.2337/dc17-2392
Pilemann-Lyberg S, Rasmussen DGK, Hansen TW, Tofte N, Winther SA, Holm Nielsen S, Theilade S, Karsdal MA, Genovese F, Rossing P: Markers of collagen formation and degradation reflect renal function and predict adverse outcomes in patients with type 1 diabetes. Diabetes Care 42: 1760–1768, 2019 https://doi.org/10.2337/dc18-2599
doi: 10.2337/dc18-2599
Horne KL, Packington R, Monaghan J, Reilly T, Selby NM: Three-year outcomes after acute kidney injury: Results of a prospective parallel group cohort study. BMJ Open 7: e015316, 2017 https://doi.org/10.1136/bmjopen-2016-015316
doi: 10.1136/bmjopen-2016-015316
Basile DP, Bonventre JV, Mehta R, Nangaku M, Unwin R, Rosner MH, Kellum JA, Ronco C; ADQI XIII Work Group: Progression after AKI: Understanding maladaptive repair processes to predict and identify therapeutic treatments. J Am Soc Nephrol 27: 687–697, 2016 https://doi.org/10.1681/ASN.2015030309
doi: 10.1681/ASN.2015030309
National Kidney Foundation. KDIGO clinical practice guideline for for the evaluation and management of chronic kidney disease (CKD). Available at https://kdigo.org/guidelines/acute-kidney-injury/https://kdigo.org/guidelines/ckd-evaluation-and-management/ . Accessed July 1, 2021
Wilson M, Packington R, Sewell H, Bartle R, McCole E, Kurth MJ, Richardson C, Shaw S, Akani A, Banks RE, Selby NM: Biomarkers during recovery from AKI and prediction of long-term reductions in estimated GFR [published online ahead of print October 12, 2021]. Am J Kidney Dis 10.1053/j.ajkd.2021.08.017
doi: 10.1053/j.ajkd.2021.08.017
Park J, Scherer PE: Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest 122: 4243–4256, 2012 https://doi.org/10.1172/JCI63930
doi: 10.1172/JCI63930
Karousou E, D’Angelo ML, Kouvidi K, Vigetti D, Viola M, Nikitovic D, De Luca G, Passi A: Collagen VI and hyaluronan: The common role in breast cancer. BioMed Res Int 2014: 606458, 2014 https://doi.org/10.1155/2014/606458
doi: 10.1155/2014/606458
Zhao Y, Gu X, Zhang N, Kolonin MG, An Z, Sun K: Divergent functions of endotrophin on different cell populations in adipose tissue. Am J Physiol Endocrinol Metab 311: E952–E963, 2016 https://doi.org/10.1152/ajpendo.00314.2016
doi: 10.1152/ajpendo.00314.2016
Funcke JB, Scherer PE: Beyond adiponectin and leptin: Adipose tissue-derived mediators of inter-organ communication. J Lipid Res 60: 1648–1684, 2019 https://doi.org/10.1194/jlr.R094060
doi: 10.1194/jlr.R094060